Phase 3 Readout
HOOK: Phase 3 Topline: A Randomized Double-blinded Phase 2/3 Study of HB-202/HB-201 Alternating 2-Vector Therapy With Pembr
April 1, 2032 · hb-202. BioSniper AI can trace the company-impact path without requiring you to write the research question.
- Event date
- April 1, 2032
- Company
- HOOKIPA Pharma Inc. (HOOK)
- Drug
- hb-202
BioSniper AIPage evidence connected
Prepared research question
What could this event change, and which evidence should be watched next?
Run cited research
Traceable citations · Unknowns marked
Phase 3 Readout~month
Phase 3 Topline: A Randomized Double-blinded Phase 2/3 Study of HB-202/HB-201 Alternating 2-Vector Therapy With Pembr
- Company
- HOOKIPA Pharma Inc. (HOOK)
- Drug
- hb-202
- Indication
- Oropharyngeal Squamous Cell Carcinoma Recurrent